Staging monoclonal plasma cell disease: Comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems

Radiology

Volumn 257, Issue 1, 2010, Pages 195-204

  Fechtner, Kerstin ^a   Hillengass, Jens ^a   Delorme, Stefan ^b   Heiss, Christiane ^a,b   Neben, Kai ^a   Goldschmidt, Hartmut ^a,c   Kauczor, Hans Ulrich ^a   Weber, Marc André ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c National Center of Tumor Diseases   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CANCER STAGING; CELL INFILTRATION; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DURIE SALMON PLUS STAGING SYSTEM; DURIE SALMON STAGING SYSTEM; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; WHOLE BODY MRI;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MONTE CARLO METHOD; PARAPROTEINEMIAS; PLASMA CELLS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 77957330530     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10091809     Document Type: Article

References (29)

1. Durie BG, Kyle RA, Belch A, et al. Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 2003;4(6):379-398. (Pubitemid 38088783)
2. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 1975;36(3):842-854.
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121(5):749-757.
4. Dimopoulos M, Terpos E, Comenzo RL, et al. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multi ple myeloma. Leukemia 2009;23(9):1545-1556.
5. Horger M, Claussen CD, Bross-Bach U, et al. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography. Eur J Radiol 2005;54(2):289-297. (Pubitemid 40523623)
6. Moulopoulos LA, Varma DG, Dimopoulos MA, et al. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. Radiology 1992;185(3):833-840.
7. Libshitz HI, Malthouse SR, Cunningham D, MacVicar AD, Husband JE. Multiple myeloma: appearance at MR imaging. Radiology 1992;182(3):833-837.
8. Daffner RH, Lupetin AR, Dash N, Deeb ZL, Sefczek RJ, Schapiro RL. MRI in the detection of malignant infiltration of bone marrow. AJR Am J Roentgenol 1986;146(2):353-358. (Pubitemid 16143933)
9. Shortt CP, Gleeson TG, Breen KA, et al. Whole-Body MRI versus PET in assessment of multiple myeloma disease activity. AJR Am J Roentgenol 2009;192(4):980-986.
10. Stäbler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF. Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996;167(4):1029-1036. (Pubitemid 26322270)
11. Mahnken AH, Wildberger JE, Gehbauer G, et al. Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. AJR Am J Roentgenol 2002;178(6):1429-1436. (Pubitemid 34547826)
12. Bäuerle T, Hillengass J, Fechtner K, et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009;252(2):477-485.
13. Kyle RA. "Benign" monoclonal gammopathy - after 20 to 35 years of follow-up. Mayo Clin Proc 1993;68(1):26-36.
14. Carter A, Tatarsky I. The physiopathological significance of benign monoclonal gammopathy: a study of 64 cases. Br J Haematol 1980;46(4):565-574. (Pubitemid 11242898)
15. Baur A, Stäbler A, Bartl R, Lamerz R, Scheidler J, Reiser M. MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol 1997;26(7):414-418.
16. Baur-Melnyk A, Reiser M. Staging of multiple myeloma with MRI: comparison to MSCT and conventional radiography [in German]. Radiologe 2004;44(9):874-881.
17. Baur-Melnyk A, Buhmann S, Dürr HR, Reiser M. Role of MRI for the diagnosis and prognosis of multiple myeloma. Eur J Radiol 2005;55(1):56-63.
18. Walker R, Barlogie B, Haessler J, et al. Magnetic resonance imaging in multiple my eloma: diagnostic and clinical implications. J Clin Oncol 2007;25(9):1121-1128. (Pubitemid 46596765)
19. Stuart A. A test for homogeneity of the marginal distribution in a two way classification. Biometrika 1955;42(3-4):412-416.
20. Agresti A. Categorical data analysis. Hoboken, NJ: Wiley, 2002.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33(1):159-174.
22. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2009.
23. Ghanem N, Lohrmann C, Engelhardt M, et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol 2006;16(5):1005-1014.
24. Edelstyn GA, Gillespie PJ, Grebbell FS. The radiological demonstration of osseous metastases: experimental observations. Clin Radiol 1967;18(2):158-162.
25. Baur-Melnyk A, Buhmann S, Becker C, et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008;190(4):1097-1104. (Pubitemid 351571514)
26. Baur A, Stäbler A, Nagel D, et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002;95(6):1334-1345.
27. Barlogie B, Anaissie E, Haessler J, et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008;113(2):355-359.
28. Hillengass J, Fechtner K, Weber MA, et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010;28(9):1606-1610.
29. Hur J, Yoon CS, Ryu YH, Yun MJ, Suh JS. Comparative study of fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for the detection of spinal bone marrow infiltration in untreated patients with multiple myeloma. Acta Radiol 2008;49(4):427-435. (Pubitemid 351598798)